marginally significantP = .057
Furthermore, the low‐dose group had a marginally significant change in the ADAS‐Cog score (adjusted P = .057).
Furthermore, the low‐dose group had a marginally significant change in the ADAS‐Cog score (adjusted P = .057).
A decreasing trend in oxidative damage was observed and reached statistical significance at the 24th week in both the low‐dose (median 0.93 [IQR: 0.71–1.03], P = .017) and high‐dose groups (median 0.94 [IQR: 0.81–1.04], P = .018) compared to the placebo group (median 1.06 [IQR: 0.96–1.19]; Figure S2 in supporting information). 3.5 Post hoc analysis There were 15 (65.2%) participants from the low‐dose group and 15 (62.5%) participants in the high‐dose group who responded to WME (defined by a 5% reduction in blood HNE level).
Though there was a trend of worse TMSE between the low‐dose and placebo group, this did not reach statistical significance.